Acute lymphoblastic leukemia - On the wings of IKAROS

New England Journal of Medicine

Volumn 360, Issue 5, 2009, Pages 524-526

  Georgopoulos, Katia ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DNA BINDING PROTEIN; IKAROS TRANSCRIPTION FACTOR; IKAROS ZINC FINGER 1; MESSENGER RNA; TRANSCRIPTION FACTOR PAX5; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; IKZF1 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CELL LINEAGE; CELL MATURATION; CHROMOSOME ABERRATION; CYTOGENETICS; DISEASE COURSE; DNA SEQUENCE; EDITORIAL; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE NUMBER; GENE TRANSLOCATION; GENETIC ASSOCIATION; GENOME; HEMATOPOIETIC STEM CELL; HIGH RISK PATIENT; HUMAN; NONHUMAN; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY MECHANISM; RELAPSE; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; ANIMAL; B LYMPHOCYTE; DRUG RESISTANCE; GENETICS; MOUSE; NOTE; PHYSIOLOGY; PROGNOSIS;

ANIMALS; B-LYMPHOCYTES; DRUG RESISTANCE, NEOPLASM; HEMATOPOIETIC STEM CELLS; HUMANS; IKAROS TRANSCRIPTION FACTOR; MICE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS;

EID: 59449091025     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0809819     Document Type: Editorial

References (12)

1. Greaves MF, Wiemels J. Origins of chromosome translocations in childhood leukaemia. Nat Rev Cancer 2003;3:639-49.
2. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007;446:758-64.
3. Cobaleda C, Schebesta A, Delogu A, Busslinger M. Pax5: the guardian of B cell identity and function. Nat Immunol 2007;8: 463-70.
4. Yoshida T, Ng SY, Zuniga-Pflucker JC, Georgopoulos K. Early hematopoietic lineage restrictions directed by Ikaros. Nat Immunol 2006;7:382-91.
5. Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008;453:110-4.
6. Iacobucci I, Lonetti A, Messa F, et al. Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance. Blood 2008;112:3847-55.
7. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360:470-80.
8. Dias S, Månsson R, Gurbuxani S, Sigvardsson M, Kee BL. E2A proteins promote development of lymphoid-primed multipotent progenitors. Immunity 2008;29:217-27.
9. Cortes M, Wong E, Koipally J, Georgopoulos K. Control of lymphocyte development by the Ikaros gene family. Curr Opin Immunol 1999;11:167-71.
10. Georgopoulos K. Haematopoietic cell-fate decisions, chromatin regulation and Ikaros. Nat Rev Immunol 2002;2:162-74.
11. Naito T, Gómez-Del Arco P, Williams CJ, Georgopoulos K. Antagonistic interactions between Ikaros and the chromatin remodeler Mi-2beta determine silencer activity and Cd4 gene expression. Immunity 2007;27:723-34.
12. Yoshida T, Hazan I, Zhang J, et al. The role of the chromatin remodeler Mi-2beta in hematopoietic stem cell self-renewal and multilineage differentiation. Genes Dev 2008;22:1174-89.